For individuals living with psoriatic arthritis, a chronic inflammatory condition affecting both joints and skin, maintaining bone health is a critical concern. New research offers encouraging evidence that long-term treatment with secukinumab, a medication that targets a specific protein in the immune system, may not only manage the symptoms of psoriatic arthritis but also help preserve bone structure over several years. What we have is particularly significant, as joint damage is a common and debilitating consequence of the disease.
The findings, published recently in RMD Open, stem from a four-year study tracking adults with active psoriatic arthritis. Researchers utilized advanced imaging techniques – high-resolution peripheral quantitative computed tomography (CT) and magnetic resonance imaging (MRI) – to assess changes in bone structure alongside clinical measures of disease activity. The study focused on the hands, a common site of inflammation and damage in psoriatic arthritis. Understanding how treatments impact bone health is crucial, as irreversible structural damage can significantly impair quality of life and long-term function.
The study enrolled 32 patients with a signify age of 56, roughly 40% of whom were female. Over the 48-month period, approximately 68.8% of participants continued secukinumab treatment. Researchers observed significant improvements across multiple disease indicators, including disease activity, inflammation of tendons (enthesitis), skin involvement, and patient-reported pain levels. Importantly, functional status, as measured by the Health Assessment Questionnaire, remained stable, suggesting that patients were able to maintain their ability to perform daily activities. These improvements were seen alongside the preservation of bone integrity, a key finding of the research.
Secukinumab’s Impact on Bone Structure
What sets this research apart is its focus on the skeletal effects of secukinumab. Using high-resolution peripheral quantitative CT, investigators found that bone density, the intricate architecture of the bone (both cortical and trabecular), and its biomechanical strength remained stable throughout the study. Crucially, there was no significant progression in the number or volume of bone erosions – areas of bone destruction characteristic of psoriatic arthritis. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) provides further information on psoriatic arthritis and its impact on joints.
MRI scans corroborated these findings. Inflammation within the joints, as detected by MRI, remained consistently low, indicating a sustained suppression of the inflammatory process. While some minor increases were observed in imaging markers related to erosion and new bone formation (osteoproliferation), the overall imaging data pointed to minimal structural progression during the long-term secukinumab therapy. This suggests that the drug effectively controls the underlying inflammation that drives bone damage.
How Secukinumab Works and Why Bone Protection Matters
Secukinumab belongs to a class of medications called interleukin-17A (IL-17A) inhibitors. IL-17A is a protein that plays a key role in the inflammatory pathways driving psoriatic arthritis. By blocking IL-17A, secukinumab reduces inflammation in the joints and skin. The National Psoriasis Foundation offers detailed information on IL-17A inhibitors and their use in treating psoriatic arthritis.
The preservation of bone structure is particularly important because structural damage in psoriatic arthritis is often irreversible and contributes to long-term disability. Erosions and changes in bone architecture can lead to chronic pain, reduced range of motion, and difficulty performing everyday tasks. Protecting bone health can therefore significantly improve a patient’s quality of life and functional capacity.
Clinical Implications and Future Research
The study’s findings have important implications for the clinical management of psoriatic arthritis. They suggest that early and sustained IL-17A inhibition with secukinumab may offer a strategy not only to control disease symptoms but also to prevent or leisurely the progression of structural damage. While the study involved a relatively small sample size, the consistent findings across multiple imaging modalities and clinical assessments strengthen the evidence supporting the osteoprotective effects of secukinumab.
Researchers noted that no major safety concerns emerged during the 48-month follow-up period. However, it’s important to remember that all medications carry potential risks and benefits, and treatment decisions should be made in consultation with a qualified healthcare professional. Further research with larger and more diverse patient populations is needed to confirm these findings and to explore the long-term effects of secukinumab on bone health in psoriatic arthritis.
The research team, led by Dr. Laura Schuster, published their findings with a DOI of 10.1136/rmdopen-2025-005857. The study, known as PSARTROS-II, provides valuable insights into the potential benefits of secukinumab beyond symptom control.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
The next step in understanding the long-term impact of secukinumab will be larger, multi-center trials designed to confirm these findings and identify potential predictors of treatment response. Researchers will also continue to investigate the underlying mechanisms by which IL-17A inhibition protects bone in psoriatic arthritis.
Have you or someone you know been affected by psoriatic arthritis? Share your experiences and thoughts in the comments below. Please also share this article with anyone who might find this information helpful.
